文献速递眼整形与眼眶神经眼科

替妥木单抗:甲状腺眼病临床试验解读与治疗现状

Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
PubMed 文献 · Ophthalmology · 2021-04-28

替妥木单抗是靶向胰岛素样生长因子1受体(IGF-1R)的单克隆抗体,美国FDA已批准用于甲状腺眼病(TED)。两项多中心随机双盲试验(170例活动期TED患者)显示,8次每3周输注替妥木单抗在眼球突出和临床活动评分(CAS)改善上优于安慰剂,但需注意听力损害和高血糖等不良事件。

要点

  • 替妥木单抗可显著改善活动期TED患者的眼球突出和CAS。
  • 常见不良事件包括肌肉痉挛、恶心、脱发、腹泻、疲劳、听力损害和高血糖。
  • 炎症性肠病和妊娠为禁忌证,剂量范围研究尚未进行。

核心结论

  • 替妥木单抗对近期起病的活动期TED患者有效,优于安慰剂。

研究设计与样本

  • 两项多中心、随机、双盲临床试验(2期和3期)评估8次每3周替妥木单抗输注对比安慰剂,共170例近期起病活动期TED患者(CAS≥4)。

主要发现

  • 2期试验总体应答率(CAS降低≥2分且眼球突出减少≥2mm)为69% vs 20%(P<0.001)。
  • 3期试验眼球突出应答率(眼球突出减少≥2mm)为83% vs 10%(P<0.001)。
  • 2期试验眼球突出平均变化为-3.0mm vs -0.3mm,CAS平均变化为-4.0 vs -2.5。
  • 3期试验眼球突出平均变化为-3.32mm vs -0.53mm,CAS平均变化为-3.7 vs -2.0。
  • 2期和3期试验中分别有62%和56%的应答者在末次给药后51周维持应答。

关键数值与推荐

  • 最常见不良事件:肌肉痉挛(25%)、恶心(17%)、脱发(13%)、腹泻(13%)、疲劳(10%)、听力损害(10%)、高血糖(8%)。
  • 禁忌证包括炎症性肠病和妊娠。

临床怎么用

  • 替妥木单抗可用于近期起病的活动期TED(CAS≥4)患者,需监测听力损害和高血糖等不良反应。
  • 禁用于炎症性肠病和妊娠患者。
  • 当前给药方案有效,但剂量范围、输注频率和疗程研究尚未进行。

局限性

  • 剂量范围研究(包括不同浓度、输注频率和疗程)尚未在TED中进行。
  • 长期维持应答数据仅至末次给药后51周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teprotumumab, a monoclonal antibody targeted against the insulin-like growth factor 1 (IGF-1) receptor, was recently approved by the United States Food and Drug Administration for the treatment of thyroid eye disease (TED). Phase 1 studies of teprotumumab for the treatment of malignancies demonstrated an acceptable safety profile but limited effectiveness. Basic research implicating the IGF-1 receptor on the CD-34+ orbital fibrocyte in the pathogenesis of TED renewed interest in the drug. Two multicenter, randomized, double-masked, clinical trials (phase 2 and 3) evaluated the efficacy of 8 infusions of teprotumumab every 3 weeks versus placebo in 170 patients with recent-onset active TED, as defined by a clinical activity score (CAS) of at least 4. Teprotumumab was superior to placebo for the primary efficacy end points in both studies: overall responder rate as defined by a reduction of 2 or more CAS points and a reduction of 2 mm or more in proptosis (69% vs. 20%; P < 0.001; phase 2 study) and proptosis responder rate as defined by a reduction of 2 mm or more in proptosis (83% vs. 10%; P < 0.001; phase 3 study). In both studies, treatment with teprotumumab compared with placebo achieved a significant mean reduction of proptosis (-3.0 mm vs. -0.3 mm, phase 2 study; -3.32 mm vs. -0.53 mm, phase 3 study) and CAS (-4.0 vs. -2.5, phase 2 study; -3.7 vs. -2.0, phase 3 study). Teprotumumab also resulted in a greater proportion of patients with a final CAS of 0 or 1, higher diplopia responder rate, and a larger improvement in the Graves' Ophthalmopathy Quality of Life overall score. More than half of patients (62%, phase 2 trial; 56%, phase 3 trial) who were primary end point responders maintained this response at 51 weeks after the last dose of therapy. The most common adverse events reported with teprotumumab included muscle spasms (25%), nausea (17%), alopecia (13%), diarrhea (13%), fatigue (10%), hearing impairment (10%), and hyperglycemia (8%). Teprotumumab is contraindicated for those with inflammatory bowel disease and who are pregnant. Although the current dosing regimen has proven effective for TED, dose-ranging studies including variable concentrations, infusion frequencies, and durations of teprotumumab therapy in the setting of TED have not been performed.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Winn BJ, Kersten RC. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies. Ophthalmology. 2021. PMID: 33930408. doi:10.1016/j.ophtha.2021.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。